Title: Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A
Brazilian Observational Multicentric Study.
Version: 1 Date: 10 Dec 2024
Reviewer's report:
This observational, retrospective multicenter study evaluated the long-term real-life
effectiveness and safety of tofacitinib in a large cohort of patients with refractory or difficult-
to-treat UC at 14 IBD centers in Brazil.
The title reflects the main subject/hypothesis of the manuscript. The abstract summarize and
reflect the work described in the manuscript. The key words reflect the focus of the manuscript.
The manuscript describe methods in adequate detail. The research objectives are achieved by
the experiments used in this study. The manuscript is well, concisely and coherently organized
and presented. Conclusions were concise and not speculative.
The study reported relevant information on real-life outcomes of tofacitinib for UC, being the
largest cases series reported till now in Latin America.
I suggest making minimal corrections in the manuscript:
- Maybee acronym of immunosuppressants better IMS or IS (instead of ISS). If you decided to
abbreviate, do so throughout the text.
- If abbreviating Janus kinase as JAK, do so throughout the text.
- It would be convenient to present the adverse effects also as: AE incidence rate (IR) per 100
patients/year (PY). This allows to compare the results with those of other studies and other drugs.
Rewrite AE section in discussion accordingly.
Title: Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A
Brazilian Observational Multicentric Study.
Version: 1 Date: 10 Dec 2024
Reviewer's report:
This observational, retrospective multicenter study evaluated the long-term real-life
effectiveness and safety of tofacitinib in a large cohort of patients with refractory or difficult-
to-treat UC at 14 IBD centers in Brazil.
The title reflects the main subject/hypothesis of the manuscript. The abstract summarize and
reflect the work described in the manuscript. The key words reflect the focus of the manuscript.
The manuscript describe methods in adequate detail. The research objectives are achieved by
the experiments used in this study. The manuscript is well, concisely and coherently organized
and presented. Conclusions were concise and not speculative.
The study reported relevant information on real-life outcomes of tofacitinib for UC, being the
largest cases series reported till now in Latin America.
I suggest making minimal corrections in the manuscript:
- Maybee acronym of immunosuppressants better IMS or IS (instead of ISS). If you decided to
abbreviate, do so throughout the text.
- If abbreviating Janus kinase as JAK, do so throughout the text.
- It would be convenient to present the adverse effects also as: AE incidence rate (IR) per 100
patients/year (PY). This allows to compare the results with those of other studies and other drugs.
Rewrite AE section in discussion accordingly.
Please review this paper.
user
Title: Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A
Brazilian Observational Multicentric Study.
Version: 1 Date: 10 Dec 2024
Reviewer's report:
This observational, retrospective multicenter study evaluated the long-term real-life
effectiveness and safety of tofacitinib in a large cohort of patients with refractory or difficult-
to-treat UC at 14 IBD centers in Brazil.
The title reflects the main subject/hypothesis of the manuscript. The abstract summarize and
reflect the work described in the manuscript. The key words reflect the focus of the manuscript.
The manuscript describe methods in adequate detail. The research objectives are achieved by
the experiments used in this study. The manuscript is well, concisely and coherently organized
and presented. Conclusions were concise and not speculative.
The study reported relevant information on real-life outcomes of tofacitinib for UC, being the
largest cases series reported till now in Latin America.
I suggest making minimal corrections in the manuscript:
- Maybee acronym of immunosuppressants better IMS or IS (instead of ISS). If you decided to
abbreviate, do so throughout the text.
- If abbreviating Janus kinase as JAK, do so throughout the text.
- It would be convenient to present the adverse effects also as: AE incidence rate (IR) per 100
patients/year (PY). This allows to compare the results with those of other studies and other drugs.
Rewrite AE section in discussion accordingly.
assistant